新辅助化疗对丹麦乳腺癌患者乳房切除即刻重建术后并发症的影响
该登记队列研究纳入2018年7月至2023年4月在丹麦奥胡斯大学医院接受乳房切除即刻重建的341例患者共459例次重建,其中53例次(11.5%)接受新辅助化疗。调整混杂因素后,新辅助化疗未增加术后并发症风险,仅小伤口并发症较少(18.9%对33.3%)。
要点
- 新辅助化疗未增加乳房切除即刻重建术后并发症风险。
- 新辅助化疗组小伤口并发症低于非化疗组(18.9%对33.3%)。
- 经选择的接受新辅助化疗患者行即刻重建可行。
核心结论
- 新辅助化疗与乳房切除即刻重建术后并发症风险增加无关。
- 新辅助化疗组小伤口并发症较少,但需谨慎解读,可能受患者特征差异和残余选择偏倚影响。
- 经选择的接受新辅助化疗患者行乳房切除即刻重建可行。
研究设计与样本
- 基于登记的队列研究,纳入2018年7月至2023年4月丹麦奥胡斯大学医院接受乳房切除即刻重建的患者。
- 共459例次即刻重建,来自341例患者;53例次(11.5%)接受新辅助化疗。
- 术后并发症数据来自病历记录,覆盖术后3个月。
主要发现
- 新辅助化疗组患者更年轻(平均年龄39.45岁对46.73岁)。
- 新辅助化疗组更常采用扩张器两阶段重建(26.4%对9.4%)。
- 新辅助化疗组28例次(52.8%)乳房发生手术并发症,非化疗组251例次(61.8%)乳房发生手术并发症。
- 调整混杂因素后,除小伤口并发症外,两组并发症率无差异;小伤口并发症新辅助化疗组为18.9%,非化疗组为33.3%。
临床怎么用
- 对经选择的乳腺癌患者,新辅助化疗后行乳房切除即刻重建未显示增加术后并发症风险。
- 新辅助化疗组小伤口并发症较少的发现需谨慎对待,应考虑患者特征差异和选择偏倚。
局限性
- 小伤口并发症差异可能受患者特征差异和残余选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neoadjuvant chemotherapy (NACT) has been used nationwide in Denmark to downsize tumour and for downstaging of metastases in the axilla. Although several studies have assessed the impact of NACT on surgical complications after immediate breast reconstruction (IBR), the available evidence remains inconsistent. This study investigates the association between NACT and surgical complications after mastectomy with IBR. METHODS: This register-based cohort study included patients who underwent mastectomy with IBR between July 2018 and April 2023 at Aarhus University Hospital, Denmark. Data on NACT and postoperative complications were obtained from medical records, covering the period three months postoperatively. RESULTS: 459 IBRs were performed in 341 patients. 53 (11.5%) breasts received NACT. Compared with the non-NACT group, patients in the NACT group were younger (mean age 39.45 versus 46.73 years) and more often underwent two-stage reconstruction with an expander (26.4% versus 9.4%). A total of 279 surgical complications were observed in 28 (52.8%) breasts in the NACT group and 251 (61.8%) breasts in the non-NACT group. After adjusting for confounding factors, no differences in complication rates were found between the two groups except for fewer minor wound complications in the NACT group (18.9% versus 33.3%). CONCLUSION: NACT was not associated with an increased risk of postoperative complications following IBR. The lower rate of minor wound complications in the NACT group should be interpreted cautiously, as differences in patient characteristics and residual selection bias may have contributed to this finding. IBR after mastectomy appears feasible in selected patients treated with NACT.
引用
- Saritas S, Brems-Eskildsen AS, Bønnelykke-Behrndtz L, et al. Effect of neoadjuvant chemotherapy on surgical outcomes in Danish breast cancer patients between 2018-2023. J Plast Reconstr Aesthet Surg. 2026. PMID: 42933286. doi:10.1016/j.bjps.2026.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。